Feb 2, 2017

House committee to take up bill targeting pharma "bad actors"


(Corrects first sentence to say bill will be considered next week and second sentence to say Schrader is a Democrat.)

The Energy and Commerce committee will take up a bipartisan bill next week to encourage generic drug development and increase market competition, Chairman Greg Walden announced at a hearing Thursday morning.

The bill by Reps. Gus Bilirakis, a Republican, and Kurt Schrader, a Democrat, would require the Food and Drug Administration to priortize and expedite the review of generic applications for drugs that are in short supply or don't have much market competition. The goal is to get at "bad actors" raising the price of old, off-patent drugs. The bill also "increases transparency" around the generic backlog at the FDA, Walden said, although he didn't give any details.

Walden, in prepared remarks, also fired a warning shot at companies like Mylan and Turing, which have bought old drugs and hiked prices: "For those in industry who think it's OK to corner a market, drive up prices and rip off consumers, know that your days are numbered."

Go deeper

Coronavirus kills 2 Diamond Princess passengers and South Korea sees first death

Data: The Center for Systems Science and Engineering at Johns Hopkins, the CDC, and China's Health Ministry. U.S. numbers include Americans extracted from Princess Cruise ship.

Two elderly Diamond Princess passengers have been killed by the novel coronavirus — the first deaths confirmed among the more than 600 infected aboard the cruise ship. South Korea also announced its first death Thursday.

The big picture: COVID-19 has now killed more than 2,200 people and infected over 75,465 others, mostly in mainland China, where the National Health Commission announced 118 new deaths since Thursday.

Go deeperArrowUpdated 4 mins ago - Health

SoftBank to cut its stake to get T-Mobile's Sprint deal done

Illustration: Rebecca Zisser/Axios

T-Mobile and Sprint announced a revised merger agreement that will see SoftBank getting a smaller share of the combined company, while most shareholders will receive the previously agreed upon exchange rate. The companies said they hope to get the deal as early as April 1.

Why it matters: The amended deal reflects the decline in Sprint's business, while leaving most shareholders' stake intact and removing another hurdle to the deal's closure.